Akebia Therapeutics (AKBA) Competitors $3.57 -0.35 (-8.93%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$3.60 +0.03 (+0.84%) As of 05:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKBA vs. CYTK, RNA, KRYS, SRPT, MRUS, ACAD, ACLX, SWTX, RARE, and PTGXShould you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Cytokinetics (CYTK), Avidity Biosciences (RNA), Krystal Biotech (KRYS), Sarepta Therapeutics (SRPT), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Akebia Therapeutics vs. Its Competitors Cytokinetics Avidity Biosciences Krystal Biotech Sarepta Therapeutics Merus ACADIA Pharmaceuticals Arcellx SpringWorks Therapeutics Ultragenyx Pharmaceutical Protagonist Therapeutics Cytokinetics (NASDAQ:CYTK) and Akebia Therapeutics (NASDAQ:AKBA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment. Which has more volatility and risk, CYTK or AKBA? Cytokinetics has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Does the MarketBeat Community prefer CYTK or AKBA? Cytokinetics received 408 more outperform votes than Akebia Therapeutics when rated by MarketBeat users. Likewise, 79.83% of users gave Cytokinetics an outperform vote while only 63.13% of users gave Akebia Therapeutics an outperform vote. CompanyUnderperformOutperformCytokineticsOutperform Votes83179.83% Underperform Votes21020.17% Akebia TherapeuticsOutperform Votes42363.13% Underperform Votes24736.87% Is CYTK or AKBA more profitable? Akebia Therapeutics has a net margin of -27.07% compared to Cytokinetics' net margin of -17,906.25%. Company Net Margins Return on Equity Return on Assets Cytokinetics-17,906.25% N/A -50.21% Akebia Therapeutics -27.07%N/A -20.57% Do institutionals and insiders believe in CYTK or AKBA? 33.9% of Akebia Therapeutics shares are owned by institutional investors. 2.7% of Cytokinetics shares are owned by company insiders. Comparatively, 3.0% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer CYTK or AKBA? In the previous week, Akebia Therapeutics had 1 more articles in the media than Cytokinetics. MarketBeat recorded 21 mentions for Akebia Therapeutics and 20 mentions for Cytokinetics. Akebia Therapeutics' average media sentiment score of 0.87 beat Cytokinetics' score of 0.35 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Akebia Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, CYTK or AKBA? Akebia Therapeutics has higher revenue and earnings than Cytokinetics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$19.22M205.76-$526.24M-$5.29-6.26Akebia Therapeutics$184.91M5.07-$51.92M-$0.21-17.00 Do analysts rate CYTK or AKBA? Cytokinetics currently has a consensus target price of $70.92, indicating a potential upside of 114.20%. Akebia Therapeutics has a consensus target price of $6.75, indicating a potential upside of 89.08%. Given Cytokinetics' higher probable upside, analysts clearly believe Cytokinetics is more favorable than Akebia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryAkebia Therapeutics beats Cytokinetics on 11 of the 18 factors compared between the two stocks. Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKBA vs. The Competition Export to ExcelMetricAkebia TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.03B$6.85B$5.57B$8.63BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-15.528.7827.1220.06Price / Sales5.07255.64412.30157.10Price / CashN/A65.8538.2534.64Price / Book-22.316.557.064.70Net Income-$51.92M$143.93M$3.23B$247.88M7 Day Performance-3.25%3.84%2.86%2.63%1 Month Performance46.91%11.20%9.07%6.36%1 Year Performance207.76%4.18%31.45%14.05% Akebia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKBAAkebia Therapeutics4.4679 of 5 stars$3.57-8.9%$6.75+89.1%+221.6%$1.03B$184.91M-15.52430High Trading VolumeCYTKCytokinetics4.4251 of 5 stars$33.13+2.6%$70.92+114.1%-37.9%$3.96B$19.22M-6.16250Trending NewsAnalyst ForecastAnalyst RevisionRNAAvidity Biosciences2.1688 of 5 stars$32.66-9.9%$67.62+107.0%+10.7%$3.94B$8.93M-11.34190Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeKRYSKrystal Biotech4.6884 of 5 stars$136.08-0.6%$211.13+55.1%-21.3%$3.93B$333.45M45.51210Positive NewsAnalyst RevisionSRPTSarepta Therapeutics4.8276 of 5 stars$39.71-7.7%$122.61+208.8%-68.8%$3.90B$2.23B31.77840High Trading VolumeMRUSMerus3.2445 of 5 stars$54.91-2.3%$85.83+56.3%-3.6%$3.80B$54.73M-13.9037ACADACADIA Pharmaceuticals3.242 of 5 stars$22.30+1.5%$26.79+20.1%+48.4%$3.73B$996.28M28.59510Trending NewsAnalyst RevisionACLXArcellx2.6591 of 5 stars$66.86-1.8%$111.33+66.5%+22.5%$3.68B$76.81M-94.1780Insider TradeAnalyst RevisionSWTXSpringWorks Therapeutics1.6116 of 5 stars$46.75-0.1%$52.57+12.5%+20.1%$3.52B$219.67M-13.43230Positive NewsHigh Trading VolumeRAREUltragenyx Pharmaceutical4.3634 of 5 stars$37.04-0.3%$88.77+139.7%-9.4%$3.50B$590.69M-5.841,310Analyst RevisionPTGXProtagonist Therapeutics2.0165 of 5 stars$55.68+2.4%$65.44+17.5%+63.0%$3.45B$207.80M20.93120Insider Trade Related Companies and Tools Related Companies CYTK Alternatives RNA Alternatives KRYS Alternatives SRPT Alternatives MRUS Alternatives ACAD Alternatives ACLX Alternatives SWTX Alternatives RARE Alternatives PTGX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKBA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKBA Stock Free AKBA Stock Alerts